Report cover image

Vascular Grafts Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

Publisher GlobalData
Published Jun 13, 2024
Length 116 Pages
SKU # GBDT18983682

Description

Vascular Grafts Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update


Summary

GlobalData's Medical Devices sector report, “Vascular Grafts Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Vascular Grafts pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Vascular grafts are tubes made up of natural tissue or synthetic materials surgically implanted in the veins and arteries. Vascular Grafts are the implants used to repair, bypass or replace sections of blood vessels during surgical procedures. They are also used to patch injured or diseased areas in the arteries and for the replacement of whole segments of larger arteries such as the aorta.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Vascular Grafts under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vascular Grafts and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vascular Grafts under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

116 Pages
    • Vascular Grafts Overview
    • Vascular Grafts - Pipeline Products by Stage of Development
    • Vascular Grafts - Pipeline Products by Segment
    • Vascular Grafts - Pipeline Products by Territory
    • Vascular Grafts - Pipeline Products by Regulatory Path
    • Vascular Grafts - Pipeline Products by Estimated Approval Date
    • Vascular Grafts - Ongoing Clinical Trials
    • Vascular Grafts Companies - Pipeline Products by Stage of Development
    • Vascular Grafts - Pipeline Products by Stage of Development
    • 3DT Holdings LLC Company Overview
    • Andes University Company Overview
    • Angiograft LLC Company Overview
    • Aquedeon Medical Inc Company Overview
    • Ariste Medical LLC Company Overview
    • Artivion Inc Company Overview
    • Aruga Technologies LLC Company Overview
    • BioDGraft GmbH Company Overview
    • BioIntegral Surgical Inc Company Overview
    • Biosurfaces Inc Company Overview
    • Cardiojustable LLC (Inactive) Company Overview
    • Cardiovate Company Overview
    • Colorado Therapeutics, LLC Company Overview
    • Cytograft Tissue Engineering Inc (Inactive) Company Overview
    • DSM Biomedical BV Company Overview
    • Eqalix, Inc. Company Overview
    • FIT Biotech Oy (Inactive) Company Overview
    • Gel-Del Technologies, Inc. Company Overview
    • Hannover Medical School Company Overview
    • Humacyte Inc Company Overview
    • Innovia LLC Company Overview
    • Merit Medical Systems Inc Company Overview
    • MicroPort Scientific Corp Company Overview
    • Nationwide Children's Hospital Company Overview
    • Northwestern University Company Overview
    • Peca Labs Inc Company Overview
    • PetVivo Holdings Inc Company Overview
    • PQ Bypass Inc Company Overview
    • RegenaGraft Company Overview
    • RUA Vascular Ltd Company Overview
    • Secant Group LLC Company Overview
    • Shanghai MicroPort Endovascular MedTech Group Co Ltd Company Overview
    • Southern University of Science and Technology Company Overview
    • Stanford University Company Overview
    • STENTiT BV Company Overview
    • Tgen Tech LLC Company Overview
    • Transmural systems LLC Company Overview
    • TTK Healthcare Ltd Company Overview
    • University of Louisville Company Overview
    • University of Nebraska Medical Center Company Overview
    • University of Pittsburgh Company Overview
    • Vascudyne Inc Company Overview
    • VenoStent Inc Company Overview
    • VesselTek BioMedical LLC Company Overview
    • VESSL Therapeutics Ltd Company Overview
    • Vygon SA Company Overview
    • Xeltis AG Company Overview
    • Yale University Company Overview
    • May 22, 2024: MicroPort Announces Board and Committee Lineup
    • Apr 13, 2024: Atrium Medical Receives Additional FDA 510(k) Clearance for Flixene IFG Vascular Grafts With Assisted Delivery
    • Apr 10, 2024: Atrium Medical Receives FDA 510(k) Clearance for Advanta VXT Vascular Graft
    • Mar 19, 2024: PECA Labs Receives Expanded CE Mark for exGraft Family of Vascular Grafts, Allowing for Expandability Designed to Match Growth or Help Avoid Restenosis
    • Mar 18, 2024: Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System
    • Mar 11, 2024: W. L. Gore & Associates Receives Additional 510(K) Clearance For GORE PROPATEN Vascular Graft
    • Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
    • Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
    • Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent
    • Feb 09, 2024: Human Acellular Vessel (HAV) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
    • Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
    • Jan 29, 2024: W. L. Gore & Associates Additional 510(K) Clearance For GORE PROPATEN Vascular Graft
    • Jan 29, 2024: Peca Labs Receives Additional FDA 510(k) Clearance for exGraft ePTFE Vascular Graft
    • Jan 29, 2024: Peca Labs Receives Additional 510(K) Clearance For exGraft Carbon ePTFE Vascular Graft
    • Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
    • Dec 20, 2023: RUA Life Sciences : Heart Valve Leaflet Material - Testing Update
    • Dec 12, 2023: Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel (HAV) for the Treatment of Vascular Trauma
    • Nov 20, 2023: RUA Life Sciences Announces Strategy Update
    • Nov 17, 2023: Humacyte Announces Two Presentations at the VEITHsymposium of Positive Clinical Results of the Human Acellular Vessel (HAV) in the Treatment of Vascular Trauma
    • Nov 10, 2023: Microport Appointment of Director
    • Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
    • Oct 19, 2023: Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results
    • Sep 21, 2023: Microport Scientific Corp. Announces 2023 Interim Report
    • Sep 18, 2023: Humacyte to Host In-Person Kol Event at the New York Edition on September 20, 2023
    • Sep 12, 2023: Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
    • Sep 11, 2023: Results From Mayo Clinic Clinical Study of Humacyte's Human Acellular Vessel (HAV) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
    • Sep 11, 2023: Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel (HAV) Tuesday, September 12, 2023 at 8:00 AM ET
    • Aug 23, 2023: Aquedeon Medical, Receives FDA IDE Approval For The Duett Vascular Graft System
    • Aug 15, 2023: Humacyte Presents Clinical Performance of Human Acellular Vessel (HAV) From Ukrainian Humanitarian Program
    • Aug 11, 2023: W. L. Gore & Associates to Present New Mosa Paper At Gvsets Conference
    • Aug 03, 2023: Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel (HAV)
    • Jul 26, 2023: Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel (HAV) for Vascular Trauma Repair
    • Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
    • Jul 11, 2023: Microport Scientific Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us